EP Patent

EP2521716B1 — Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof

Assigned to Ardea Biociences Inc · Expires 2015-12-30 · 10y expired

What this patent protects

Patent listed against Aloprim.

Drugs covered by this patent

Patent Metadata

Patent number
EP2521716B1
Jurisdiction
EP
Classification
—
Expires
2015-12-30
Drug substance claim
No
Drug product claim
No
Assignee
Ardea Biociences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.